Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.
XPhyto Therapeutics’ German subsidiary, Vektor Pharma TF has finalized the formula for its novel transdermal delivery system (TDS) for the neurologic drug Rotigotine, which approved for the treatment of Parkinson's disease and restless legs syndrome in Europe and the US.
Rotigotine, the active pharmaceutical ingredient, is a generic off-patent drug that is typically formulated as a once-daily transdermal patch to provide a slow and constant supply of the drug over the course of 24 hours.
The company claims it has optimized the dosage form efficiency to reduce the amount of drug required in each patch and improved overall patch adhesion to the patient's skin.
Vektor is now focused on process implementation for the manufacture of Rotigotine TDS clinical samples for use in human pilot studies. The parameters for increased manufacturing capacity are currently being evaluated with a final decision expected to be made within 30 days.
Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020.
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
Piramal acquires solid oral dosage drug product facility from G&W Laboratories
22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.Read more
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment
22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.Read more
Sanofi to build EUR 490 million vaccine production facility in France
16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccinesRead more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation